Conclusion. Ceftobiprole is a novel, broad-spectrum, parenteral cephalosporin undergoing Phase III clinical trials. Its broad spectrum of activity makes it a candidate for monotherapy of cSSSIs ...

and specific broad-spectrum antibiotics known to contribute most to antibiotic resistance (co-amoxiclav, quinolones, and cephalosporins). Secondly, a fixed amount of tax per unit of the drug.

Credit: Getty Images. Ceftobiprole is a broad spectrum cephalosporin antibiotic. The Food and Drug Administration (FDA) has accepted the New Drug Application for ceftobiprole, an investigational ...

Cephalosporins belong to a family of antibiotics ... the more we can reduce the use of broad-spectrum antibiotics such as fluoroquinolones, which is generally the mainstay of treatment for kidney ...

Cephalosporins belong to a family of antibiotics ... the more we can reduce the use of broad-spectrum antibiotics such as fluoroquinolones, which is generally the mainstay of treatment for kidney ...

The COVID-19 pandemic has highlighted the urgent need for antiviral drugs with a broad spectrum of activity—both to treat current infections and to prevent possible new pathogens with pandemic ...

Ceftobiprole has the potential to be used as monotherapy for the treatment of pneumonia and cSSSIs. Patients with DFIs and osteomyelitis were excluded from the cSSSI clinical trials, and ...